per hour for family and patient respondents, and $75 per hour for physicians. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

ESTIMATE OF ANNUAL HOUR BURDEN [2010–2013]

<table>
<thead>
<tr>
<th>Type of response</th>
<th>Number of respondents</th>
<th>Frequency of response</th>
<th>Average time per response</th>
<th>Annual hour burden</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant Follow-up</td>
<td>10,735</td>
<td>1.0</td>
<td>0.2500</td>
<td>2,683.8</td>
</tr>
<tr>
<td>Physician or Coroner (for CHD)</td>
<td>491</td>
<td>1.0</td>
<td>0.1667</td>
<td>81.8</td>
</tr>
<tr>
<td>Physician (for heart failure)</td>
<td>190</td>
<td>1.0</td>
<td>0.0833</td>
<td>15.8</td>
</tr>
<tr>
<td>Participant’s next-of-kin</td>
<td>575</td>
<td>1.0</td>
<td>0.1667</td>
<td>95.9</td>
</tr>
<tr>
<td>Total</td>
<td>11,992</td>
<td>1.0</td>
<td>0.2399</td>
<td>2,877.4</td>
</tr>
</tbody>
</table>

1 Annual burden is placed on doctors, hospitals, nursing homes, and respondent relatives/informants through requests for information which will help in the compilation of the number and nature of new fatal and nonfatal events.

Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, OFFA_submission@omb.eop.gov or by fax to 202–395–6974, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Hanyu Ni, NIH, NHLBI, 6701 Rockledge Drive, MSC 7934, Bethesda, MD 20892–7934, or call non-toll-free number (301) 435–0448 or E-mail your request, including your address to: hanyun@nhlbi.nih.gov.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.
Services Administration’s (SAMHSA) Drug Testing Advisory Board (DTAB) will meet on March 8, 2010.

The meeting is open to the public and will include discussion of the Mandatory Guidelines for Federal Workplace Drug Testing Programs, including implementation of the revised Mandatory Guidelines; Federal drug testing updates from the Department of Transportation (DOT), the Department of Defense, and the Nuclear Regulatory Commission; review of significant changes in the revised Mandatory Guidelines; review of the National Laboratory Certification Program planned implementation of the revised Mandatory Guidelines; an update on the revised Federal Custody and Control Form; a review of the special proficiency testing program for initial and confirmation testing for new analytes and new cutoffs; an update on instrumented initial test facilities; an update on the DTAB working groups; and a comparison of HHS and DOT urine collection requirements.

DTAB members and invited presenters will participate in this meeting through remote internet connection. On-site attendance by the public will be limited to space available. The meeting can also be accessed by the public via teleconference. To obtain teleconference call-in numbers and access codes, make arrangements to attend on-site, or to request special accommodations for persons with disabilities, please register at the SAMHSA Committees’ Web site at https://nac.samhsa.gov/Registration/meetingsRegistration.aspx or communicate with DTAB’s Program Assistant, Ms. Giselle Hersh (see contact information below).

SAMHSA would like to ensure that advisory committee meetings proceed in an orderly fashion, are conducted in a safe and secure environment, that the right of free speech is protected, and that the ability of SAMHSA Advisory Committees to accomplish their objectives is not disrupted. Therefore, the following procedures will be followed at all DTAB meetings:

- Attendees are subject to security screening, including identification (driver’s license) review, metal detector screening, and inspection of briefcases, packages, etc. Each attendee will be issued a security badge that must be worn at all times while in the building.
- Any interested person who wishes to be assured of the right to make an oral presentation during the Public Comment portion of the DTAB meeting must register with Ms. Hersh before the meeting.
- Those who have not registered before the meeting will only be invited to speak at the discretion of the Chair and must submit their request to the Designated Federal Official on the day of the meeting.
- Public Comment participants who are designated to speak may be questioned only by the Chair or DTAB members.
- Audience members may not present comments or questions to DTAB members unless recognized by the Chair.
- Attendees at the meeting are asked to maintain order and not display behavior that is disruptive to the meeting (i.e., shouting from the audience, loud outbursts).
- We ask that attendees do not approach the DTAB table area during the meeting without permission from the Chair or the Designated Federal Official.
- The DTAB Chair or Designated Federal Official will note on the record any disruptive behavior and will ask the person to cease the behavior or else leave the meeting room.
- Substantive program information, a summary of the meeting, and a roster of DTAB members may be obtained as soon as possible after the meeting by accessing the SAMHSA Committee Web site. https://nac.samhsa.gov/DTAB/meetings.aspx or by contacting Ms. Hersh. The transcript for the meeting will also be available on the SAMHSA Committee Web site within three weeks after the meeting.

Committee Name: Substance Abuse and Mental Health Services Administration, Drug Testing Advisory Board.

Date/Time/Type: March 8, 2010 from 10 a.m. to 4:45 p.m. EST; Open.

Place: Sugarloaf and Seneca Conference Rooms, 1 Choke Cherry Road, Rockville, Maryland 20857.

Contacts:
Ms. Giselle Hersh, Program Assistant, SAMHSA Drug Testing Advisory Board, 1 Choke Cherry Road, Room 2–1042, Rockville, Maryland 20857. Telephone: 240–276–2600, Fax: 240–276–2610, E-mail: Giselle.Hersh@samhsa.hhs.gov

Toian Vaughn,
Committee Management Officer, Substance Abuse and Mental Health Services Administration.

[BFR Doc. 2010–3227 Filed 2–18–10; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications. Such disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Initial Review Group, Minority Programs Review Subcommittee B.

Date: March 8–9, 2010.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Hotel Palomar—Washington, DC, Washington, DC 20037.

Contact Person: Rebecca H. Johnson, PhD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN18C, Bethesda, MD 20892, 301–594–2771, johnsonrh@nigms.nih.gov.

Name of Committee: National Institute of General Medical Sciences Initial Review Group. Minority Programs Review Subcommittee A.

Date: March 8, 2010.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Courtyard Marriott Chevy Chase, Chevy Chase, MD 20815.

Contact Person: Mona R. Trempe, PhD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3AN12, Bethesda, MD 20892, 301–594–3998, trempeom@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)


Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010–3200 Filed 2–18–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications. Such disclosure of which would constitute a clearly unwarranted invasion of personal privacy.